Su KY - Search Results

1

R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability.

Chen HY, Yu SL, Ho BC, Su KY, Hsu YC, Chang CS, Li YC, Yang SY, Hsu PY, Ho H, Chang YH, Chen CY, Yang HI, Hsu CP, Yang TY, Chen KC, Hsu KH, Tseng JS, Hsia JY, Chuang CY, Yuan S, Lee MH, Liu CH, Wu GI, Hsiung CA, Chen YM, Wang CL, Huang MS, Yu CJ, Chen KY, Tsai YH, Su WC, Chen HW, Chen JJ, Chen CJ, Chang GC, Yang PC, Li KC. Chen HY, et al. Among authors: su wc, su ky. J Clin Oncol. 2015 Jul 10;33(20):2303-10. doi: 10.1200/JCO.2014.59.3590. Epub 2015 Jun 8. J Clin Oncol. 2015. PMID: 26056182

2

Mice deficient in collapsin response mediator protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory.

Su KY, Chien WL, Fu WM, Yu IS, Huang HP, Huang PH, Lin SR, Shih JY, Lin YL, Hsueh YP, Yang PC, Lin SW. Su KY, et al. J Neurosci. 2007 Mar 7;27(10):2513-24. doi: 10.1523/JNEUROSCI.4497-06.2007. J Neurosci. 2007. PMID: 17344389 Free PMC article.

3

Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.

Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, Wu CP, Shih JY, Yang PC. Chang TH, et al. Among authors: su ky. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9. doi: 10.1164/rccm.201009-1440OC. Epub 2010 Oct 29. Am J Respir Crit Care Med. 2011. PMID: 21037017

4

Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E.

Ho BC, Yu SL, Chen JJ, Chang SY, Yan BS, Hong QS, Singh S, Kao CL, Chen HY, Su KY, Li KC, Cheng CL, Cheng HW, Lee JY, Lee CN, Yang PC. Ho BC, et al. Among authors: su ky. Cell Host Microbe. 2011 Jan 20;9(1):58-69. doi: 10.1016/j.chom.2010.12.001. Cell Host Microbe. 2011. PMID: 21238947 Free article.

5

Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.

Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, Chen HW, Chen CY, Yu CJ, Shih JY, Chang YL, Cheng CL, Hsu CP, Hsia JY, Lin CY, Wu G, Liu CH, Wang CD, Yang KC, Chen YW, Lai YL, Hsu CC, Lin TC, Yang TY, Chen KC, Hsu KH, Chen JJ, Chang GC, Li KC, Yang PC. Yuan S, et al. Among authors: su ky. J Clin Oncol. 2011 Sep 1;29(25):3435-42. doi: 10.1200/JCO.2011.35.3979. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810691

6

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC. Su KY, et al. J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Epub 2012 Jan 3. J Clin Oncol. 2012. PMID: 22215752

7

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.

Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC. Tseng JS, et al. Among authors: su ky. Onco Targets Ther. 2014 May 23;7:799-805. doi: 10.2147/OTT.S62639. eCollection 2014. Onco Targets Ther. 2014. PMID: 24920920 Free PMC article.

8

Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer.

Chen CC, Chen HY, Su KY, Hong QS, Yan BS, Chen CH, Pan SH, Chang YL, Wang CJ, Hung PF, Yuan S, Chang GC, Chen JJ, Yang PC, Yang YC, Yu SL. Chen CC, et al. Among authors: su ky. Am J Respir Crit Care Med. 2014 Aug 15;190(4):433-44. doi: 10.1164/rccm.201312-2256OC. Am J Respir Crit Care Med. 2014. PMID: 25036006

9

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.

Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Wu CW, Yang CT, Chen YM, Chang GC. Tseng JS, et al. Among authors: su ky. PLoS One. 2014 Sep 12;9(9):e107160. doi: 10.1371/journal.pone.0107160. eCollection 2014. PLoS One. 2014. PMID: 25215536 Free PMC article.

10

Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.

Tseng JS, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Chen JJ, Chang GC. Tseng JS, et al. Among authors: su ky. J Thorac Oncol. 2015 Apr;10(4):603-10. doi: 10.1097/JTO.0000000000000443. J Thorac Oncol. 2015. PMID: 25514801 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

158 results

Search Page